Table 1. Summary of case reports on Fosmanogepix.

HSCT: Hematopoietic stem cell transplantation; HL: Hodgkin's lymphoma; GVHD: Graft-versus host disease; AML: Acute myeloid leukemia; FMGX: Fosmanogepix; AMB: Amphotericin B

Author (s)	Case summary	Duration of Therapy	Outcome
Camargo et al. [40]	A 40-year-old male who underwent HSCT for Hodgkin's lymphoma (HL) experienced complications with graft-versus-host disease (GvHD) and subsequently developed a disseminated infection with multi-drug-resistant Aspergillus calidoustus	It is approximately 191 days, though it is not explicitly mentioned	Significant improvement with negative serum galactomannan
Winston et al. [45]	A 26-year-old with AML faced a Fusarium lactis infection, resistant to azoles and echinocandins. FMGX combined with liposomal AMB	6 months	Clinical improvement, reductions in brain lesions, and an absolute neutrophil count rise, resulting in AML remission
Goggin et al. [46]	A 14-year-old with immunodeficiency and end-stage kidney disease has had persistent cutaneous Fusariosis since age 3. Despite prior unsuccessful treatments, FMGX was successful, leading to negative skin biopsies	6 months	Clinical improvement with negative skin biopsies